20 diciembre 2023

A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease ( SAHARA ) .

Si Nos Fijamos Solo en la I+D Para el Tratamiento del OJO SECO Hay Actualmente 1669 Ensayos Clínicos en Marcha :

Si Nos Fijamos en la I+D Para el Tratamiento de Ojo Seco en Personas con Syndrome de Sjogren ( Qué es la Indicación en la Que va Dirigida TIVANISIRAN By Sylentis ) Hay Actualmente 254 Ensayos Clínicos en Marcha :

Treated With TearCare^® Should Be a Preferred Treatment For Eye Disease ( DED ) Associated With MGD .

Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) .

TearCare^®Provides Statistically Superior And Sustained Improvement In TBUT And Múltiple Measures Of Meibomian Gland Secretion, And Non-Inferior Improvement In OSDI, Corneal And Conjuntival Staining, SANDE, EDS, And STS Versus CsA . ...

20 diciembre 2023

A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease ( SAHARA ) .

Treated With TearCare® Should Be a Preferred Treatment For Eye Disease ( DED ) Associated With MGD .

Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) .

TearCare® Provides Statistically Superior And Sustained Improvement In TBUT And Múltiple Measures Of Meibomian Gland Secretion, And Non-Inferior Improvement In OSDI, Corneal And Conjuntival Staining, SANDE, EDS, And STS Versus CsA . ...

Treated With TearCare^® Should Be a Preferred Treatment For Eye Disease ( DED ) Associated With MGD .

TearCare^®Provides Statistically Superior And Sustained Improvement In TBUT And Múltiple Measures Of Meibomian Gland Secretion, And Non-Inferior Improvement In OSDI, Corneal And Conjuntival Staining, SANDE, EDS, And STS Versus CsA . ...